Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs

• Type: Article in International Scientific Journal
• Date: 2012

Authors

Helguera, AM (Author) Other; Perez Machado, G (Author) Other; Cordeiro, MNDS (Author) FCUP; Borges, F (Author) FCUP

Journal

Title: Mini-Reviews in Medicinal Chemistry

Vol. 12

Pages: 907-919

ISSN: 1389-5575

Publisher: Bentham Science

Indexing

ISI Web of Knowledge - 37 Citations

Scopus - 43 Citations

Scientific classification

FOS: Natural sciences > Chemical sciences

CORDIS: Physical sciences > Chemistry > Applied chemistry > Pharmaceutical chemistry

Other information

Authenticus ID: P-002-64Y

DOI: 10.2174/138955712802762301

Abstract (EN): Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The role of monoamine oxidase (MAO) inhibitors has expanded in the PD treatment. The present review will summarize the current structure-activity relationship information available on MAOs inhibitors of unrelated families of compounds of oxygen heterocyclic type based on coumarin, chromone and chalcone scaffolds. As the current hitting-one-target therapeutic strategy has been proved to be quite inefficient in PD, this review will also discuss about the development of multi-target drugs, in which MAO inhibition plays a counter-part, as a novel and promising treatment approach for PD.

Language: English

Type (Professor's evaluation): Scientific